RNVA Rennova Health Inc (PK)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Diamantis Christopher Eric	2. Issuer Name and Ticker or Trading Symbol Rennova Health, Inc. [ RNVA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    __X__ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 1143 GLENDALE LANE	3. Date of Earliest Transaction (MM/DD/YYYY) 8/27/2021
(Street) NASHVILLE,, TN 37204 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	8/27/2021		J(1)		95000000	A	(1)	95450000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to Purchase Common Stock	$0.007	8/27/2021		J (1)		47500000		8/27/2021 (2)	8/27/2024	Common Stock	47500000	(1)	47500000	D
Series M Convertible Redeemable Preferred Stock	(3)	8/27/2021		J (1)			570	(2)	(2)	Common Stock	(3)	(1)	20180	D

Explanation of Responses:
(1)	On August 27, 2021, pursuant to the terms of an Exchange Agreement with the Issuer, Mr. Diamantis exchanged 570 shares of Series M Redeemable Convertible Preferred Stock of the Issuer (the "Series M Preferred Stock") for 95,000,000 shares of Common Stock and Warrants to purchase 47,500,000 shares of Common Stock.
(2)	The exercise of the Warrants and the conversion of the Series M Preferred Stock are each subject to ownership blockers of 4.99%. As a result, they are not exercisable or convertible as of August 27, 2021. The Series M Preferred Stock has no stated maturity date.
(3)	The conversion price of the Series M Preferred Stock fluctuates with the price of the Common Stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Diamantis Christopher Eric 1143 GLENDALE LANE NASHVILLE,, TN 37204		X

Signatures
/s/ Christopher E. Diamantis		9/27/2021
**Signature of Reporting Person		Date